JO
TLIS

John Overdeck’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

John Overdeck’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,187
Closed -$14K – 2919
2022
Q2 		$14K Sell
1,187
-3,735
-76% -$59.1K ﹤0.01% 2425
2022
Q1 		$104K Sell
4,922
-320
-6% -$11.1K ﹤0.01% 2427
2021
Q4 		$315K Buy
+5,242
New +$392K ﹤0.01% 3615

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John Overdeck's TLIS Position: Q3 2022 in Review

John Overdeck sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2022, closing a stake of 1,187 shares — an estimated $14K sold.

John Overdeck first reported a position in TLIS in Q4 2021 and held it in 3 quarters. The position peaked at $315K in Q4 2021. 29 funds tracked by Wall St. Rank hold TLIS as of Q3 2022.

  • John Overdeck reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2022 after selling out during the quarter.
  • John Overdeck sold 1,187 Talis Biomedical Corporation Common Stock shares in Q3 2022, an estimated $14K.
  • John Overdeck first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and held it in 3 quarters.
  • John Overdeck's Talis Biomedical Corporation Common Stock position peaked at $315K in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2022.

Based on Two Sigma Investments's 13F filing for Q3 2022, filed 14 Nov 2022.